1. Home
  2. SPRO vs SIEB Comparison

SPRO vs SIEB Comparison

Compare SPRO & SIEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • SIEB
  • Stock Information
  • Founded
  • SPRO 2013
  • SIEB 1886
  • Country
  • SPRO United States
  • SIEB United States
  • Employees
  • SPRO N/A
  • SIEB N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • SIEB Investment Bankers/Brokers/Service
  • Sector
  • SPRO Health Care
  • SIEB Finance
  • Exchange
  • SPRO Nasdaq
  • SIEB Nasdaq
  • Market Cap
  • SPRO 121.0M
  • SIEB 110.4M
  • IPO Year
  • SPRO 2017
  • SIEB N/A
  • Fundamental
  • Price
  • SPRO $1.90
  • SIEB $2.93
  • Analyst Decision
  • SPRO Buy
  • SIEB
  • Analyst Count
  • SPRO 4
  • SIEB 0
  • Target Price
  • SPRO $5.00
  • SIEB N/A
  • AVG Volume (30 Days)
  • SPRO 391.2K
  • SIEB 67.2K
  • Earning Date
  • SPRO 08-12-2025
  • SIEB 11-11-2025
  • Dividend Yield
  • SPRO N/A
  • SIEB N/A
  • EPS Growth
  • SPRO N/A
  • SIEB N/A
  • EPS
  • SPRO N/A
  • SIEB 0.24
  • Revenue
  • SPRO $48,576,000.00
  • SIEB $86,037,000.00
  • Revenue This Year
  • SPRO N/A
  • SIEB N/A
  • Revenue Next Year
  • SPRO N/A
  • SIEB N/A
  • P/E Ratio
  • SPRO N/A
  • SIEB $11.88
  • Revenue Growth
  • SPRO N/A
  • SIEB 9.07
  • 52 Week Low
  • SPRO $0.51
  • SIEB $1.87
  • 52 Week High
  • SPRO $3.22
  • SIEB $5.77
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 39.50
  • SIEB 46.04
  • Support Level
  • SPRO $1.91
  • SIEB $2.48
  • Resistance Level
  • SPRO $2.18
  • SIEB $2.63
  • Average True Range (ATR)
  • SPRO 0.10
  • SIEB 0.18
  • MACD
  • SPRO 0.01
  • SIEB 0.06
  • Stochastic Oscillator
  • SPRO 19.18
  • SIEB 82.26

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SIEB Siebert Financial Corp.

Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.

Share on Social Networks: